Amgen's Engine

Sharer on acquisitions

While Amgen Inc.'s two blockbuster drugs, Epogen erythropoietin and Neupogen filgrastim G-CSF, came from internal development programs, more than half of the company's pipeline is derived from partnerships with or acquisitions of other biotech companies. And of the company's four late-stage products, two were in-licensed or acquired.

CEO-designate Kevin Sharer said he intends to continue AMGN's search for outside product opportunities to complement the company's internal research. "The view of Amgen has been more of a do-it-yourself company than a buy it or license it company," Sharer told BioCentury. "I'm not sure that's totally accurate. We have not been as active on the 'buy a company' front, but we have